This article is part of a Chronicle. See more from this Chronicle Keith Hylton, Jul 15, 2015 For the last decade or so, the FTC has had a bee in its bonnet over “reverse payment settlements.” Such a settlement occurs when a pioneer pharmaceutical firm terminates a patent infringement lawsuit against a generic drug maker […]
This article is part of a Chronicle. See more from this Chronicle Alden Abbott, Mar 16, 2015 The setting of industry standards is widely recognized as a driver of economic growth—standards may reduce production costs; increase innovation, efficiency (through greater product interoperability, for example), and consumer choice; foster public health and safety; and facilitate international […]
Aug 14, 2014 CPI Asia Column edited by Vanessa Zhang (Global Economics Group) presents: Antitrust Regulation of IPRS – China’s First Proposal – Adrian Emch (Hogan Lovells) & Liyang Hou (KoGuan Law School, Shanghai Jiao Tong University)1 Click here for a pdf version of this article. Introduction On June 11, 2014, the State Administration for […]
This article is part of a Chronicle. See more from this Chronicle Michael Carrier, Aug 22, 2014 In the past several years, standard essential patents, or “SEPs,” have exploded onto the scene. Courts and enforcement agencies around the world have grappled with the nuances they present. What exactly are SEPs? What do attorneys need to […]
This article is part of a Chronicle. See more from this Chronicle Donald Falk, Christopher Kelly, Apr 29, 2014 As with patent infringement litigation in many industries, innovator pharmaceutical companies frequently settle their patent infringement litigation against would-be generic challengers by licensing the alleged infringer to market its generic version of the patented drug before […]
Dec 20, 2013 To have the incentive to undertake research and development, a firm must be able to appropriate returns sufficient to make the investment worthwhile. The benefits consumers derive from an innovation, however, are increased if competitors can imitate and improve on the innovation to ensure its availability on favorable terms. Patent law seeks […]
David Evans, Dec 20, 2013 There are several areas of economics where we know much more today than we did 50 years ago as a result of the accumulation of empirical research. More needs to be done, and much remains debated, but economists have made real progress in behavioral economics, labor economics, and financial economics. […]
Fiona Scott Morton, Dec 20, 2013 This article lays out the economics of competition between branded and generic pharmaceuticals and its welfare consequences. I explain the logic behind so-called “pay-for-delay” or “reverse payments” in the context of the current IP environment where weak (probabilistic) patents are frequently granted by the PTO. The article goes on […]
Pierre Regibeau, Dec 20, 2013 Antitrust concerns about “pay-for-delay” patent settlements are based on two theories of harms, one that stresses the need for courts to review the validity of patents and one that emphasizes the “probabilistic” nature of patent rights. The main weakness of the first theory of harm is that it fails to […]
Douglas Ginsburg, Joshua Wright, Dec 20, 2013 In modern antitrust law, intellectual property rights (IPRs) are treated like all other forms of property. Beginning with the Department of Justice Antitrust Division’s repudiation of the “Nine No-No’s” for patent licensing more than thirty years ago, the US antitrust enforcement agencies and the courts have adhered to […]